These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 28810622)

  • 1. Oral N-acetylcysteine for prophylaxis of contrast-induced nephropathy in patients following coronary angioplasty: A meta-analysis.
    Li JX; Jin EZ; Yu LH; Li Y; Liu NN; Dong YM; Li X; Li XQ
    Exp Ther Med; 2017 Aug; 14(2):1568-1576. PubMed ID: 28810622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials.
    Sun Z; Fu Q; Cao L; Jin W; Cheng L; Li Z
    PLoS One; 2013; 8(1):e55124. PubMed ID: 23383076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-acetylcysteine and contrast-induced nephropathy: a meta-analysis of 13 randomized trials.
    Zagler A; Azadpour M; Mercado C; Hennekens CH
    Am Heart J; 2006 Jan; 151(1):140-5. PubMed ID: 16368307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of combination therapy of high-dose oral N-acetylcysteine and intravenous sodium bicarbonate hydration with individual therapies in the reduction of Contrast-induced Nephropathy during Cardiac Catheterisation and Percutaneous Coronary Intervention (CONTRAST): A multi-centre, randomised, controlled trial.
    Chong E; Poh KK; Lu Q; Zhang JJ; Tan N; Hou XM; Ong HY; Azan A; Chen SL; Chen JY; Ali RM; Fang WY; Lau TW; Tan HC
    Int J Cardiol; 2015 Dec; 201():237-42. PubMed ID: 26301645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The efficacy of N-acetylcysteine plus sodium bicarbonate in the prevention of contrast-induced nephropathy after cardiac catheterization and percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Zhao SJ; Zhong ZS; Qi GX; Tian W
    Int J Cardiol; 2016 Oct; 221():251-9. PubMed ID: 27404685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with pre-existing renal insufficiency or diabetes: a systematic review and meta-analysis.
    Kang X; Hu DY; Li CB; Ai ZS; Peng A
    Ren Fail; 2015 Nov; 37(10):297-303. PubMed ID: 26458505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of N-Acetylcysteine for the Prevention of Contrast-Induced Nephropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Xu R; Tao A; Bai Y; Deng Y; Chen G
    J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27663415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials.
    Ma WQ; Zhao Y; Wang Y; Han XQ; Zhu Y; Liu NF
    Int Urol Nephrol; 2018 Jun; 50(6):1085-1095. PubMed ID: 29404930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of N-Acetylcysteine in preventing contrast-induced nephropathy in patients undergoing contrast-enhanced computed tomography: a meta-analysis of randomized controlled trials.
    Wu MY; Hsiang HF; Wong CS; Yao MS; Li YW; Hsiang CY; Bai CH; Hsu YH; Lin YF; Tam KW
    Int Urol Nephrol; 2013 Oct; 45(5):1309-18. PubMed ID: 23283594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect.
    Webb JG; Pate GE; Humphries KH; Buller CE; Shalansky S; Al Shamari A; Sutander A; Williams T; Fox RS; Levin A
    Am Heart J; 2004 Sep; 148(3):422-9. PubMed ID: 15389228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrarenal application of N-acetylcysteine for the prevention of contrast medium-induced nephropathy in primary angioplasty.
    Aslanger E; Uslu B; Akdeniz C; Polat N; Cizgici Y; Oflaz H
    Coron Artery Dis; 2012 Jun; 23(4):265-70. PubMed ID: 22343798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does N-acetylcysteine reduce the incidence of contrast-induced nephropathy and clinical events in patients undergoing primary angioplasty for acute myocardial infarction?
    Tanaka A; Suzuki Y; Suzuki N; Hirai T; Yasuda N; Miki K; Fujita M; Tanaka T
    Intern Med; 2011; 50(7):673-7. PubMed ID: 21467697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trimetazidine reduces contrast-induced nephropathy in patients with renal insufficiency undergoing coronary angiography and angioplasty: A systematic review and meta-analysis (PRISMA).
    Heshmatzadeh Behzadi A; Amoozgar B; Jain S; Velasco N; Zahid U; Abbasi H; Alasadi L; Prince MR
    Medicine (Baltimore); 2021 Mar; 100(10):e24603. PubMed ID: 33725824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetylcysteine versus ascorbic acid or N-acetylcysteine plus ascorbic acid in preventing contrast-induced nephropathy: A meta-analysis.
    Feng Y; Huang X; Li L; Chen Z
    Nephrology (Carlton); 2018 Jun; 23(6):530-538. PubMed ID: 28452187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized trial of intravenous n-acetylcysteine to prevent contrast induced nephropathy in acute coronary syndromes.
    Jaffery Z; Verma A; White CJ; Grant AG; Collins TJ; Grise MA; Jenkins JS; McMullan PW; Patel RA; Reilly JP; Thornton SN; Ramee SR
    Catheter Cardiovasc Interv; 2012 May; 79(6):921-6. PubMed ID: 21542122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trimetazidine Decreases Risk of Contrast-Induced Nephropathy in Patients With Chronic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials.
    Nadkarni GN; Konstantinidis I; Patel A; Yacoub R; Kumbala D; Patel RA; Annapureddy N; Pakanati KC; Simoes PK; Javed F; Benjo AM
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):539-46. PubMed ID: 25715308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylcysteine has No Mechanistic Effect in Patients at Risk of Contrast-Induced Nephropathy: A Failure of Academic Clinical Science.
    Sandilands EA; Rees JMB; Raja K; Dhaun N; Morrison EE; Hickson K; Wraight J; Gray T; Briody L; Cameron S; Thompson AP; Johnston NR; Uren N; Goddard J; Treweeke A; Rushworth G; Webb DJ; Bateman DN; Norrie J; Megson IL; Eddleston M
    Clin Pharmacol Ther; 2022 Jun; 111(6):1222-1238. PubMed ID: 35098531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.